Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.